Oncogenes in solid human tumours - PubMed (original) (raw)

. 1982 Dec 9;300(5892):539-42.

doi: 10.1038/300539a0.

• PMID: 7144906
• DOI: 10.1038/300539a0

Oncogenes in solid human tumours

S Pulciani et al. Nature. 1982.

No abstract available

PubMed Disclaimer

Similar articles

• Insulin-like growth factors: the unrecognised oncogenes.
  Westley BR, May FE. Westley BR, et al. Br J Cancer. 1995 Nov;72(5):1065-6. doi: 10.1038/bjc.1995.465. Br J Cancer. 1995. PMID: 7577447 Free PMC article. No abstract available.
• Antigens expressed on NIH 3T3 cells following transformation with DNA from human pancreatic tumor.
  Hollingsworth MA, Rebellato LM, Moore JW, Finn OJ, Metzgar RS. Hollingsworth MA, et al. Cancer Res. 1986 May;46(5):2482-7. Cancer Res. 1986. PMID: 3697988
• Cellular transforming genes and oncogenesis.
  Cooper GM, Lane MA. Cooper GM, et al. Biochim Biophys Acta. 1984;738(1-2):9-20. doi: 10.1016/0304-419x(84)90017-9. Biochim Biophys Acta. 1984. PMID: 6331501 Review. No abstract available.
• Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling.
  Minamoto T, Ougolkov AV, Mai M. Minamoto T, et al. Expert Rev Mol Diagn. 2002 Nov;2(6):565-75. doi: 10.1586/14737159.2.6.565. Expert Rev Mol Diagn. 2002. PMID: 12465453 Review.
• ras oncogenes in human cancer: a review.
  Bos JL. Bos JL. Cancer Res. 1989 Sep 1;49(17):4682-9. Cancer Res. 1989. PMID: 2547513 Review.

Cited by

• Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights.
  Mahajan AT, Shivani, Datusalia AK, Coluccini C, Coghi P, Chaudhary S. Mahajan AT, et al. Molecules. 2024 Jul 29;29(15):3560. doi: 10.3390/molecules29153560. Molecules. 2024. PMID: 39124968 Free PMC article. Review.
• Identification of FLRT2 as a key prognostic gene through a comprehensive analysis of TMB and IRGPs in BLCA patients.
  Tao Y, Yu X, Cong H, Li J, Zhu J, Ding H, Chen Q, Cai T. Tao Y, et al. Front Oncol. 2024 Feb 29;13:1229227. doi: 10.3389/fonc.2023.1229227. eCollection 2023. Front Oncol. 2024. PMID: 38486936 Free PMC article.
• NTRK Therapy among Different Types of Cancers, Review and Future Perspectives.
  Theik NWY, Muminovic M, Alvarez-Pinzon AM, Shoreibah A, Hussein AM, Raez LE. Theik NWY, et al. Int J Mol Sci. 2024 Feb 17;25(4):2366. doi: 10.3390/ijms25042366. Int J Mol Sci. 2024. PMID: 38397049 Free PMC article. Review.
• Selective type II TRK inhibitors overcome xDFG mutation mediated acquired resistance to the second-generation inhibitors selitrectinib and repotrectinib.
  Xiang S, Lu X. Xiang S, et al. Acta Pharm Sin B. 2024 Feb;14(2):517-532. doi: 10.1016/j.apsb.2023.11.010. Epub 2023 Nov 8. Acta Pharm Sin B. 2024. PMID: 38322338 Free PMC article. Review.
• Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.
  Malik P, Rani R, Solanki R, Patel VH, Mukherjee TK. Malik P, et al. Explor Target Antitumor Ther. 2023;4(5):850-895. doi: 10.37349/etat.2023.00171. Epub 2023 Oct 10. Explor Target Antitumor Ther. 2023. PMID: 37970206 Free PMC article. Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • Cellosaurus - a cell line knowledge resource